HCV PI Tier 1 – The Approach to the Patient with HCV Infection (Archived Webinar)
Hepatitis C (HCV) is a major health problem. It can lead to cirrhosis, liver failure, or liver cancer and is the nation’s leading reason for liver transplants. This illness now causes more deaths than HIV in the United States. HCV is particularly a problem for baby boomers; nearly 75 percent of Americans with hepatitis C were born between 1945 and 1965. Effective treatment is vital to cure patients and prevent progression and deaths from cirrhosis and liver cancer.
The program features baseline knowledge about the care of the patient with Hepatitis C, including a review of the pathophysiology of Hepatitis C, the recommended quality and performance metrics, and the systemic or patient challenges that a healthcare provider might face during the care of Hepatitis C patients. Participants will also learn about new DAA therapies and other soon-to-be released Hepatitis C treatments; including how to implement the new agents, review of the specific treatment algorithms as approved by the FDA, monitoring for side effects, and challenges of timing viral load determinations.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance